The molecular pathways of EMT in ovarian cancer cells mediated by PARD6A-Integrin β1-ILK-SNAIL1 and finally implemented by E-cadherin and VIMENTIN also provide a novel strategy for drug development in the future (Fig. 7I). This evidence concerns the gene PARD6A and ovarian carcinoma.